Core Viewpoint - The study highlights the role of Cathepsin-D (CTSD) in immune evasion in microsatellite stable colorectal cancer (MSS CRC), suggesting that targeting CTSD can enhance the efficacy of anti-PD-1 therapies [2][3][5]. Group 1: Research Findings - CTSD is overexpressed in colorectal cancer, leading to immune evasion and treatment resistance [7]. - CTSD promotes the degradation of MHC-I through the lysosomal pathway, which hinders its recycling to the cell surface [5][7]. - Gene knockout or pharmacological inhibition of CTSD can block immune evasion and enhance the efficacy of anti-PD-1 therapy [6][9]. Group 2: Implications for Treatment - Targeting CTSD in conjunction with anti-PD-1 immunotherapy could potentially improve treatment outcomes for patients with MSS CRC [8][9].

Core Viewpoint - The study highlights the potential of the probiotic Clostridium butyricum to enhance the efficacy of anti-PD-1 therapy in colorectal cancer by inhibiting IL-6-mediated immunosuppression [3][4][6]. Group 1: Research Findings - Clostridium butyricum is identified as a probiotic that can improve the effectiveness of anti-PD-1 therapy in colorectal cancer models [6]. - The study demonstrated that Clostridium butyricum enhances tumor suppression in both microsatellite instability-high (MSI-H) and microsatellite stable (MSS) colorectal cancer models [6]. - Single-cell RNA sequencing revealed that Clostridium butyricum activates cytotoxic CD8+ T lymphocytes and inhibits tumor-associated macrophages, particularly when used in combination with anti-PD-1 therapy [6][7]. Group 2: Mechanism of Action - The surface protein secD of Clostridium butyricum binds to the receptor GRP78 on colorectal cancer cells, leading to the inactivation of GRP78 and suppression of the PI3K-AKT-NF-κB pathway, which reduces the secretion of the immunosuppressive cytokine IL-6 [7]. - IL-6 is known to inhibit cytotoxic T lymphocytes and induce tumor-associated macrophages, thus its reduction is crucial for enhancing anti-tumor immunity [7]. Group 3: Clinical Implications - The study's findings suggest that Clostridium butyricum could be a promising adjunct to immune checkpoint blockade therapies in colorectal cancer, potentially improving patient outcomes [10]. - The research establishes a foundation for the clinical application of Clostridium butyricum in enhancing anti-PD-1 therapy effectiveness [7][10].